A structural analog of sphingosine that is phosphorylated in vivo to form fingolimod-phosphate, which functions as an agonist at S1P1, S1P4, and S1P5 receptors (EC50 = ~0.3-0.6 nM) and at 10-fold higher concentrations at S1P3 receptors (EC50 = ~3 nM); orally bioavailable compound with efficacy in advanced clinical trials for the treatment of MS through receptor-mediated actions both on the immune system and in the CNS.